Writing a prescription
Source: Tetra Images/Getty Images

The Innovation Institute—a for-profit company comprising six member owner health systems—announced it has chosen 2bPrecise to leverage its cloud-based, EHR agnostic platform to deliver pharmacogenomics information to the clinical point of care for the Institute’s members, as well as other health systems outside the network.

Under the terms of the agreement, 2bPrecise will leverage its precision medicine platform to allow clinicians to access the information from GeneFolio, a pharmacogenomics test and knowledge base developed by Avera Health, to help guide medication selection for individual patients based on their genetic profile.

“Pharmacogenomics is poised for rapid healthcare adoption to improve treatment success and Avera has been developing and advancing the integration for almost a decade,” said Krista Bohlen, PharmD, director of personalized medicine at the Avera Institute for Human Genetics, in a prepared statement. “We’re excited to offer this test, developed by Avera scientists, laboratory personnel and pharmacists that will serve as a guide for a patient’s care for decades to come.”

The GeneFolio test uses either saliva or blood to test for relevant genes that can inform precision medication selection in three specific areas: pain management, depression and other psychiatric disorders, and statins for cholesterol and certain types of blood thinners. After patient testing, 2bPrecise will deliver the GeneFolio results directly to the point of care within the existing electronic workflow. The reports are color coded to show which medications will be metabolized by the patient, as well as which medications should be used with caution, and those that should be avoided.

“The GeneFolio knowledge base is truly revolutionary,” said Larry Stofko, executive vice president of The Innovation Institute, in a press release, “and 2bPrecise is the perfect partner to help us achieve our mission. Together, we can enable physicians to take these insights, and order the medications or therapies most likely to be effective with each individual patient. This means improved patient outcomes and a decrease in the overall cost of care.”

Delivery of the results to clinicians via the 2bPrecise platform is not only within Avera’s network in the Midwest, but also to the other five members of The Innovation Institute comprising 125 hospitals in 20 states. Other members include Bon Secours Health System, CHOC Children's, Franciscan Missionaries of Our Lady, Mercy Health, and Providence St. Joseph Health.

Also of Interest